

ESMO PRECEPTORSHIP

CAPE TOWN SOUTH AFRICA **6-7 FEBRUARY 2025**

Co-Chairs

Sheynaz Bassa, South Africa Ilaria Colombo, Switzerland



ESMO PRECEPTORSHIP PROGRAMME CERVICAL CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Cape Town, South Africa 6-7 February 2025

CO-CHAIRS

Sheynaz Bassa, South Africa Ilaria Colombo, Switzerland **SPEAKERS**

Henriette Burger, South Africa
Jackie Chokoe Maluleke, South Africa
Surbhi Grover, Botswana
Nomonde Mbatani, South Africa
Edwin Mnisi, South Africa
Kgomotso Mokoala, South Africa
Dina Najjari Jamal, Spain
Ana Oaknin, Spain
Dominic Richards, South Africa
MNC Vilakazi, South Africa

LEARNING OBJECTIVES

- To learn about screening, prevention and diagnosis of cervical cancer
- To understand the standard of care management of early, locally advanced and metastatic cervical cancer
- To learn how to treat complications of cervical cancer and manage special situations
- To understand the important role of multidisciplinary management of cervical cancer

ACCREDITATION

The programme of this event has been accredited with 9 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.o

Email: courses@esmo.org www.esmo.org



Thursday, 6 February 2025

09:00-09:05 5'	Welcome and introduction	Sheynaz Bassa, ZA Ilaria Colombo, CH
09:05-10:50 105'	SESSION 1 Epidemiology, prevention and diagnosis of cervical cancer	Chair: Ilaria Colombo, CH
20'	The epidemiology of cervical cancer in Africa	Sheynaz Bassa, ZA
20'	Vaccination and screening programs: Opportunities and challenges	Nomonde Mbatani, ZA
20'	From precursor lesions to invasive cancer: The pathologist perspective	Jackie Chokoe Maluleke, ZA
15'	Imaging in cervical cancer: The radiology perspective	MNC Vilakazi, ZA
15'	Imaging in cervical cancer: The nuclear medicine perspective	Kgomotso Mokoala, ZA
15'	Q&A	All
10:50-11:20	Coffee break	
11:20-12:50 90'	SESSION 2 Treatment of early stage cervical cancer	Chair: Ilaria Colombo, CH
30'	Principles of surgical treatment, including fertility sparing approaches	Edwin Mnisi, ZA
15'	When is adjuvant treatment indicated?	Sheynaz Bassa, ZA
15'	Q&A	All
30'	Clinical case presentations from the audience (2x15')	Faculty
12:50-13:50	Lunch	
13:50-15:55 125'	SESSION 3 Treatment of locally-advanced cervical cancer	Chair: Sheynaz Bassa, ZA
30'	Chemoradiotherapy and brachytherapy: When, how and new techniques	Dina Najjari Jamal, ES
20'	Role of systemic treatment: How can we do better?	Ilaria Colombo, CH
15'	The role (or challenge) of a multidisciplinary tumour board in Africa	Surbhi Grover, BW
15'	Q&A	All
45'	Clinical case presentations from the audience (3x15')	Faculty
15:55-16:25	Coffee break	
16:25-17:55 90'	SESSION 4 Treatment of recurrent and metastatic cervical cancer - Part 1	Chair: Sheynaz Bassa, ZA
15'	Role of re-irradiation in recurrent disease	Dina Najjari Jamal, ES
15	Role of surgery in recurrent disease	Dominic Richards, ZA
20'	Systemic treatment: Chemotherapy and beyond	Ana Oaknin, ES
20'	Palliative care and treatment of complications	Henriette Burger, ZA
20'	Q&A	All
20:00	Dinner	

Friday, 7 February 2025

09:00-9:45 45'	SESSION 5 Treatment of recurrent and metastatic cervical cancer - Part 2	Chair: Ilaria Colombo, CH
45'	Clinical case presentations from the audience (3x15')	Faculty
9.45-10:55 70'	SESSION 6 How to deal with special situations	Chair: Sheynaz Bassa, ZA
20'	Treatment of HIV positive patients	Surbhi Grover, BW
20'	Treatment of rare histological subtypes	Ana Oaknin, ES
20'	Cervical cancer and pregnancy	Nomonde Mbatani, ZA
10'	Q&A	All
10:55-11:00 5'	Conclusion and farewell	Sheynaz Bassa, ZA Ilaria Colombo, CH

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion